Logo image of ARVN

ARVINAS INC (ARVN) Stock Overview

USA - NASDAQ:ARVN - US04335A1051 - Common Stock

9.525 USD
-0.12 (-1.3%)
Last: 10/28/2025, 11:30:15 AM

ARVN Key Statistics, Chart & Performance

Key Statistics
Market Cap699.33M
Revenue(TTM)372.80M
Net Income(TTM)-72600000
Shares73.42M
Float68.30M
52 Week High28.83
52 Week Low5.9
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.01
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11/bmo
IPO2018-09-27
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ARVN short term performance overview.The bars show the price performance of ARVN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

ARVN long term performance overview.The bars show the price performance of ARVN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ARVN is 9.525 USD. In the past month the price increased by 13.13%. In the past year, price decreased by -64.13%.

ARVINAS INC / ARVN Daily stock chart

ARVN Latest News, Press Relases and Analysis

ARVN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 50.51 772.08B
JNJ JOHNSON & JOHNSON 18.07 451.80B
AZN ASTRAZENECA PLC-SPONS ADR 18.73 257.84B
NVS NOVARTIS AG-SPONSORED ADR 14.06 240.92B
NVO NOVO-NORDISK A/S-SPONS ADR 13.33 230.35B
MRK MERCK & CO. INC. 11.31 217.43B
PFE PFIZER INC 7.25 139.72B
SNY SANOFI-ADR 11.53 124.17B
BMY BRISTOL-MYERS SQUIBB CO 6.39 87.53B
GSK GSK PLC-SPON ADR 9.81 88.39B
ZTS ZOETIS INC 23.54 64.89B
TAK TAKEDA PHARMACEUTIC-SP ADR 50.45 44.61B

About ARVN

Company Profile

ARVN logo image Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 430 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Company Info

ARVINAS INC

5 Science Park

New Haven CONNECTICUT 06511 US

CEO: John Houston

Employees: 430

ARVN Company Website

ARVN Investor Relations

Phone: 12035351456

ARVINAS INC / ARVN FAQ

What does ARVINAS INC do?

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 430 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.


What is the stock price of ARVINAS INC today?

The current stock price of ARVN is 9.525 USD. The price decreased by -1.3% in the last trading session.


What is the dividend status of ARVINAS INC?

ARVN does not pay a dividend.


What is the ChartMill rating of ARVINAS INC stock?

ARVN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists ARVN stock?

ARVN stock is listed on the Nasdaq exchange.


What sector and industry does ARVINAS INC belong to?

ARVINAS INC (ARVN) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the number of employees for ARVINAS INC?

ARVINAS INC (ARVN) currently has 430 employees.


ARVN Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ARVN. When comparing the yearly performance of all stocks, ARVN is a bad performer in the overall market: 88.45% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ARVN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ARVN. ARVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARVN Financial Highlights

Over the last trailing twelve months ARVN reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 80.46% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.98%
ROE -11.92%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-71.43%
Sales Q2Q%-70.72%
EPS 1Y (TTM)80.46%
Revenue 1Y (TTM)73.48%

ARVN Forecast & Estimates

27 analysts have analysed ARVN and the average price target is 12.24 USD. This implies a price increase of 28.5% is expected in the next year compared to the current price of 9.525.

For the next year, analysts expect an EPS growth of 55.22% and a revenue growth -2.7% for ARVN


Analysts
Analysts75.56
Price Target12.24 (28.5%)
EPS Next Y55.22%
Revenue Next Year-2.7%

ARVN Ownership

Ownership
Inst Owners93.89%
Ins Owners2.15%
Short Float %10.92%
Short Ratio3.6